Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Altruix
Deal Size : Undisclosed
Deal Type : Partnership
Altruix Approved to Dispense Brixadi® for Moderate to Severe Opioid Use Disorder
Details : Under the partnership, Altruix has been selected as a limited distribution partner for Brixadi (buprenorphine), an opioid medication and an extended-release subcutaneous injection indicated for the treatment of moderate to severe opioid use disorder pati...
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 17, 2023
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Altruix
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRIXADI is an investigational, extended-release SC injectable therapy under review by FDA for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product.
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRIXADI, SC injection, will be indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 02, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Braeburn Resubmits New Drug Application for BRIXADI
Details : BRIXADI is an investigational, extended-release injection for subcutaneous use that is under review by FDA for the treatment of moderate to severe opioid use disorder, and expects to receive a PDUFA date in 30 days.
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 15, 2021
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Camurus
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pivotal Phase 3 efficacy and safety trial demonstrated that Brixadi met the primary endpoint of non-inferiority for responder rate vs current standard of care and superiority for the secondary endpoint for the percentage of negative opioid assessment...
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 01, 2020
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Camurus
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Medpace, Inc | Camurus
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Buprenorphine is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Low Back Pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 26, 2016
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Medpace, Inc | Camurus
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-9242
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
Details : ATI-9242 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 07, 2016
Lead Product(s) : ATI-9242
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of Risperidone Implants
Details : Risperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 16, 2016
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAS 52485-79-7
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Pharmacokinetics Study of CAM2038
Details : CAM2038 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Related Disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 16, 2016
Lead Product(s) : CAS 52485-79-7
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAS 52485-79-7
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
Details : CAM2038 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Opioid-Related Disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 03, 2016
Lead Product(s) : CAS 52485-79-7
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable